Ciprofloxacin (Bay-09867), a synthetic broad spectrum fluoroquinolone antibiotic, inhibits bacterial DNA gyrase. It is more active against Gram-negative bacteria than Gram-positive bacteria.

Ciprofloxacin（1 mg/L）可诱导GST活性，与此相反，暴露于恩诺沙星的幼虫其GST和CAT活性受到抑制。Ciprofloxacin（≥10 μg/L）和恩诺沙星对两栖类动物幼虫的发育、生长、解毒及抗氧化应激酶具有生态毒性[4]。Ciprofloxacin 对Y. pestis显示出强大的活性，其MIC90为0.03 μg/mL[2]。在肺鼠疫的鼠类模型中，Ciprofloxacin（30 mg/kg，i.p.）所达到的化合物暴露程度，与人类口服500 mg剂量的Ciprofloxacin后观察到的化合物暴露程度相似。腹腔注射 Ciprofloxacin 可较对照组的腹腔注射PBS更有效地减少肺部细菌负荷[5]。

The in vitro kinase assays is performed by incubating purified kinase (IKKε or TBK1) in kinase buffer containing 25 mM Tris (pH7.5), 10 mM MgCl2, 1 mM DTT, and 10 μM ATP for 30 minutes at 30°C in the presence of 0.5 μCi γ-[32P]-ATP and 1 μg MBP per sample as a substrate. The kinase reaction is stopped by adding 4x sodium dodecyl sulfate (SDS) sample buffer and boiling for 5 minutes at 95°C. Supernatants are resolved by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose, and analyzed by autoradiography using a Typhoon 9410 phosphorimager.